CD38 and neoplasm: The results suggest that the rapid clearance of the CD38-targeted small molecule imaging agents from healthy non-target tissues combined with their specific tumor uptake will enable longitudinal evaluation of CD38 expression during disease progression and monitoring of minimal residual disease after therapy, paving the way for clinical translation, and significantly improving the management of patients with MM.